From November 1994 to November 1997 we investigated 133 patients with alloantibodies directed against high-frequency red cell antigens (Ab-HFA). More than 90% of these antibodies were found in females. Interestingly, all carriers of anti-Lu b/8 and 7 of 13 persons with anti-Yta were pregnant women. The majority of the Ab-HFA (n = 69, 51.9%) belonged to the clinically insignificant high-titer low-avidity (HTLA) antibodies with anti-Cha as the leading specificity (n = 47, 33.8%). The remaining HTLA specificities were anti-Kna (n = 9), anti-Rga (n = 4), anti-JMH (n = 3), anti-Yka (n = 3), anti-Sda (n = 2), and anti-McCa (n = 1). In 32 additional cases (24.1%), Ab-HFA of uncertain or low clinical significance were detected: anti Yta (n = 13), anti-Lu b/8 (n = 13), anti-Coa (n = 3), anti-Ge (n = 2), one anti-AnWj.Thus, Ab-HFA of no or uncertain clinical significance achieved a proportion of roughly 75%. Clinically significant antibodies were demonstrable in 29 (22%) patients: anti-Vel (n = 14), anti-Lan (n = 5), anti-Kpb (n = 3), anti-k (n = 2), anti-Jk3 (n = 2), anti-KL (n = 1), anti-Tja (n = 1), anti-Dib (n = 1). Hemolytic transfusion reactions were noted in 6 cases (4.5%); 3 of them occurred with anti-Vel and 3 with anti-Lan. Mild hemolytic disease of the newborn was observed in one case of anti-k. Three cases remained unresolved (2%). Multiple additional red cell alloantibodies, i. e. anti-Rh, anti-K, anti-Fy and others, were present in 24 patients (18.1%) with Ab-HFA, predominantly associated with anti-Yta (57%) and anti-Cha . Most importantly, the serological reactions of Ab-HFA were weak, uniform and difficult to differentiate from nonspecific reactions. Careful serological testing with a large panel of rare test cells is necessary to distinguish the harmful from the harmless Ab-HFA.

This content is only available via PDF.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.